On 28th November OxTalks will move to the new Halo platform and will become 'Oxford Events' (full details are available on the Staff Gateway).
There will be an OxTalks freeze beginning on Friday 14th November. This means you will need to publish any of your known events to OxTalks by then as there will be no facility to publish or edit events in that fortnight. During the freeze, all events will be migrated to the new Oxford Events site. It will still be possible to view events on OxTalks during this time.
If you have any questions, please contact halo@digital.ox.ac.uk
Rita De Santis directs the Department of Biotech Products at Sigma Tau SpA, Italy. Rita’s group previously published that injected oxidised Avidin, called AvidinOX, exhibits the distinctive property to form Schiff’s bases with tissue proteins thus constituting a stable receptor for biotinylated therapeutics. AvidinOX is currently under clinical investigation in Europe and USA to target radioactive biotin to inoperable tumor masses. Previous data also proved that AvidinOX can be employed for targeting biotinylated cells or biotinylated antibodies. Interestingly, a strong anti-tumor activity of AvidinOX-anchored biotinylated Cetuximab (bCet) was observed, against EGFR+ tumor cells. The talk will illustrate how to exploit this unexpected result for new cancer therapies.
